Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Subscribe To Our Newsletter & Stay Updated